News

Mie Wolff Kristensen Since the introduction of combination immunotherapy and TKIs, treatment outcomes for mRCC patients have improved markedly with a subset of patients achieving durable or complete responses. Despite these results, a large group of patients do not respond to treatment, and therefore, selecting the right treatment for the right patient is crucial. Treatment […]

By Mads Hvid Poulsen, PhDConsultant, Head of Research, Associate ProfessorDepartment for Urology, Esbjerg and Grindsted Hospital, University Hospital of Southern DenmarkDepartment of Regional Health Research, University of Southern Denmark Prostate cancer remains the most frequently diagnosed malignancy in men across Europe, and early detection through screening has the potential to improve survival outcomes. However, the […]

In the era of targeted tyrosine kinase inhibitor therapy two randomized trials, CARMENA and SURTIME, have questioned the role and timing of CN in synchronous mRCC patients with results pointing towards an improved benefit upon a deferred approach; except for IMDC poor risk patients. The deferred CN approach ensures systemic therapy for all patients, avoids […]